

Market snapshot



Equities - India	Close	Chg .%	CYTD.%
Sensex	80,182	-0.6	11.0
Nifty-50	24,199	-0.6	11.4
Nifty-M 100	58,723	-0.6	27.2
Equities-Global	Close	Chg .%	CYTD.%
S&P 500	5,872	-2.9	23.1
Nasdaq	19,393	-3.6	29.2
FTSE 100	8,199	0.0	6.0
DAX	20,243	0.0	20.8
Hang Seng	7,181	1.1	24.5
Nikkei 225	39,082	-0.7	16.8
Commodities	Close	Chg .%	CYTD.%
Brent (US\$/Bbl)	75	1.7	-3.6
Gold (\$/OZ)	2,585	-2.3	25.3
Cu (US\$/MT)	8,910	0.5	5.3
Almn (US\$/MT)	2,486	-0.5	6.0
Currency	Close	Chg .%	CYTD.%
USD/INR	85.0	0.1	2.1
USD/EUR	1.0	-1.3	-6.2
USD/JPY	154.8	0.9	9.8
YIELD (%)	Close	1MChg	CYTD chg
10 Yrs G-Sec	6.7	-0.01	-0.4
10 Yrs AAA Corp	7.3	-0.01	-0.5
Flows (USD b)	18-Dec	MTD	CYTD
FII	-0.2	2.74	0.8
DII	0.48	1.80	60.2
Volumes (INRb)	18-Dec	MTD*	YTD*
Cash	1,119	1146	1261
F&O	2,15,016	1,88,109	3,68,167

Note: Flows, MTD includes provisional numbers.

*Average



Today's top research idea

MTAR Technologies: Fueling clean energy liftoff

- ❖ MTARTECH derives the majority of its revenue (~60% in 1HFY25) from the clean energy segments, with most of it coming from one customer, Bloom Energy (BE). As the transitory impact of BE's product changes is over now, we expect the company to report strong growth in the near term in this segment, led by the revival of orders from BE and the addition of new clients.
- ❖ MTARTECH witnessed a rough patch over the last couple of quarters due to product transition by BE. As the transition is completed, we are witnessing strong demand for BE's fuel cells, thereby boosting our confidence on the company's near-term growth outlook.
- ❖ BE is witnessing a surge in demand as it has signed large deals recently, e.g., an agreement with American Electric Power (AEP) to install 1GW of power over the next couple of years. This opportunity has a revenue potential of INR9-11b for MTARTECH.
- ❖ To further diversify its customer mix, MTARTECH has been adding new clients across segments, such as Fluence Energy, which has similar revenue potential as BE in the near future.
- ❖ MTARTECH, a key supplier of precision-engineered systems, benefits from growing fuel cell demand, particularly as the largest supplier to BE. We expect MTARTECH to deliver a CAGR of 28%/42%/58% in revenue/EBITDA/Adj. PAT over FY24-27.




Research covered

Cos/Sector	Key Highlights
MTAR Technologies	Fueling clean energy liftoff
Financials	ICRA Webinar on NBFC-MFIs sector outlook
Technology	Healthcare vertical: A pause in the party?



Chart of the Day: MTAR Technologies (Fueling clean energy liftoff)

Clean Energy – Fuel cells expected to retrace its growth trajectory



Source: MOFSL

Research Team (Gautam.Duggad@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.



Kindly click on textbox for the detailed news link

1

ABB to buy power electronics business from Siemens Gamesa

ABB has agreed to acquire the power electronics unit of Gamesa Electric in Spain from Siemens Gamesa to boost its position in the renewable power conversion technology market.

2

Asian Paints' Top Two Executives Resign Citing 'Personal Circumstances'

Asian Paints confirmed that Shyam Swamy, vice president of home improvement, and Vishu Goel, associate vice president of retail sales, have stepped down due to personal reasons.

3

Borosil Renewables unveils ₹675-crore expansion plan and ₹700-crore fundraising

The board of directors have approved key decisions, including a temporary cooldown of its German subsidiary's furnace, a production capacity expansion in India, and revised fundraising strategies to support growth amid improving market conditions.

4

Brigade Enterprises launches net-zero residential project, Citrine, at GDV of Rs 500 crore

The company has launched India's first net-zero residential project with an estimated Gross Development Value (GDV) of about Rs 500 crore, with project size of 4.3 acre, having 420 residential units.

5

Lupin receives FDA approval for generic HIV tablets

Lupin is one of the first companies to receive approval for this formulation originally developed by Gilead Sciences, making it eligible for 180 days of shared generic exclusivity in the US market.

6

Gandhar Oil Refinery says USFDA closed inspection on co's Talaja facility

Gandhar Oil Refinery says USFDA closed inspection on co's Talaja facility.

7

FDC gets USFDA approval for Cefixime 400 mg tablets to treat bacterial infections

Cefixime is used to treat bacterial infections in many different parts of the body. It belongs to the class of medicines known as cephalosporin antibiotics.



MTAR Technologies

BSE SENSEX
80,182

S&P CNX
24,199

CMP: INR1556 TP: INR2,100 (+35%)

Buy



Building Nation with Exceptional Engineering

Stock Info

Bloomberg	MTARTECH IN
Equity Shares (m)	31
M.Cap.(INRb)/(USDb)	47.9 / 0.6
52-Week Range (INR)	2353 / 1495
1, 6, 12 Rel. Per (%)	-7/-21/-46
12M Avg Val (INR M)	541
Free float (%)	63.6

Financials Snapshot (INR b)

Y/E MARCH	2025E	2026E	2027E
Sales	7.4	9.2	12.2
EBITDA	1.5	2.3	3.2
Adj. PAT	0.8	1.4	2.2
EBITDA Margin (%)	20.9	24.5	26.5
Cons. Adj. EPS (INR)	27.0	46.5	71.9
EPS Gr. (%)	48.0	72.1	54.7
BV/Sh. (INR)	246.9	293.4	365.3

Ratios

Net D:E	0.2	0.1	0.0
RoE (%)	11.6	17.2	21.8
Payout (%)	11.0	15.8	20.6

Valuations


P/E (x)	57.7	33.5	21.7
EV/EBITDA (x)	32.0	21.5	14.9

Shareholding Pattern (%)

As On	Sep-24	Jun-24	Sep-23
Promoter	36.4	36.4	39.1
DII	17.3	16.0	24.1
FII	7.8	7.8	8.8
Others	38.5	39.9	28.0

FII includes depository receipts

Stock Performance (one-year)



Fueling clean energy liftoff


MTARTECH derives the majority of its revenue (~60% in 1HFY25) from the clean energy segments, with most of it coming from one customer, Bloom Energy (BE). As the transitory impact of BE's product changes is over now, we expect the company to report strong growth in the near term in this segment, led by the revival of orders from BE and the addition of new clients.

- MTARTECH witnessed a rough patch over the last couple of quarters due to product transition by BE. As the transition is completed, we are witnessing strong demand for BE's fuel cells, thereby boosting our confidence on the company's near-term growth outlook.
- BE is witnessing a surge in demand as it has signed large deals recently, e.g., an agreement with American Electric Power (AEP) to install 1GW of power over the next couple of years. This opportunity has a revenue potential of INR9-11b for MTARTECH.
- To further diversify its customer mix, MTARTECH has been adding new clients across segments, such as Fluence Energy, which has similar revenue potential as BE in the near future.
- MTARTECH, a key supplier of precision-engineered systems, benefits from growing fuel cell demand, particularly as the largest supplier to BE. We expect MTARTECH to deliver a CAGR of 28%/42%/58% in revenue/EBITDA/Adj. PAT over FY24-27.

Client concentration risk has played out – what's next?

- BE is the largest customer of MTARTECH, accounting for ~70% of its total revenue in FY24. BE is the global leader in manufacturing standard oxide fuel cells (SOFC).
- MTARTECH supplies critical components such as hotboxes (named Santacruz) to BE, which are used in a fuel cell where the chemical reaction to generate power takes place. Moreover, MTARTECH also supplies electrolyzers, sheet metals and wiring to BE.
- MTARTECH currently caters to ~70-75% of BE's hotbox requirements, making the former a key vendor. The company is also looking to increase its wallet share with BE by providing more services, with an end target of fully assembling fuel cells for BE in India.
- The client concentration risk has been a key concern for MTARTECH, as seen in FY24 when BE went into product transition to Santacruz (65kw energy generation) from Yuma (50kw). This led to a slowdown in BE's order flows to MTARTECH, thereby impacting the company's revenue and profitability. Revenue from clean energy fuel cells declined by 21% YoY in FY24 vs. 2.2x growth in FY23.
- However, the transition was completed two quarters ago and we are seeing normalized order flows from BE. In 2QFY25, the clean energy fuel cell segment posted 9% YoY growth vs. a decline in the last four quarters.

South Korea Demand



- Going ahead, we expect strong growth in this segment as the closing order book for BE as of 1HFY25 stood at INR4.9b. BE is returning to the original demand scenario as it has indicated an execution of 4,000 units in CY25 vs. 3,000 units indicated earlier. Further to this, BE have been witnessing strong demand tailwinds in the recent period as discussed in detail below.

BE witnessing strong demand tailwinds

- We have further analyzed BE’s demand scenario to gauge the order flow trends for MTARTECH.
- Over the last few years, BE has signed multiple large agreements to scale up its clean energy technology across diverse industries and geographies.
- **Some of the large deals include:** SK ecoplant (in Dec’23) to deliver 500MW SOFC through 2027 generating ~USD1.5b in product revenue and USD3b in service revenue over 20 years for BE; Parenco (Jun’24) in UK to install 2.5MW SOFC in the largest commercial procurement of fuel cells with an initial order of 100MW and a potential expansion to 1GW focusing on powering AI data centers.
- BE has expanded its existing partnership with Quanta Computers, aiming to deliver more than 150% of the power capacity provided in the client’s existing installations. Other notable collaborations are with CoreWeave and Amazon.
- Additionally, BE orders include deployments for decarbonizing the industrial sectors, powering AI/data centers, and enhancing energy resilience. Collectively, these orders contribute to BE’s projected revenue path of USD1.8b for the next fiscal year.
- BE’s proven track record, with over 1.3GW deployed globally, and its capacity to scale up production for large orders make it a significant player in clean and reliable energy solutions.
- **Since MTARTECH is BE’s largest vendor, the company benefits significantly from strong order flows from BE. For instance, under a recent agreement with AEP, BE will supply ~15,000 hotboxes to AEP. For MTARTECH, it can translate into INR10-11b in revenue (refer exhibit 1) over the next couple of years (incremental to current order book).**

Expanding clientele in clean energy space

- Apart from the key client (BE) coming back on track with a strong outlook, MTARTECH has been proactive in diversifying its client base to safeguard from the client concentration risk in the future.
- One such addition in clean energy is Fluence Energy (Fluence). Fluence, established in 2018, is a leading global provider of energy storage products and services. It is a joint venture between Siemens AG and AES Corporation.
- Fluence collaborates with MTARTECH to address India’s growing need for renewable energy integration and grid stability.
- As per the indications from MTARTECH’s management, the revenue potential from Fluence can be similar to BE in the near future.
- Currently, the contribution from Fluence is nil as Fluence has not yet won any orders in India, but when it does, the orders from Fluence will start flowing in to MTARTECH.

Valuation and view


- MTARTECH, being the key supplier of precision engineered systems to large global MNCs, government departments, and large Indian public and private sector enterprises, has over the years created a niche for itself in the industry.
- As the largest supplier of fuel cell components to BE (global leader), the company will benefit from the emerging demand for fuel cells in the coming years. Further, the company is also increasing its wallet share with BE by offering more products, such as precision sheet metal fabrication and enclosures, with the aim of carrying out a complete fuel cell integration for BE.
- We believe the BE-related headwind is over now, and going ahead, strong order flows and agreements by BE should boost the business scenario for MTARTECH. Moreover, the diversification across segments by the company is expected to result in healthy revenue growth going ahead.
- We estimate MTARTECH to deliver a CAGR of 28%/42%/58% in revenue/ EBITDA/adj. PAT over FY24-27 on the back of strong order inflows. We retain our BUY rating on the stock with a TP of INR2,100 (34x Dec'26E EPS).

Opportunity size of AEP orders for MTAR

Particulars	Metrics	Units	Units
AEP potential order for BE	MW		1000
Hotboxes needed			
Santacruz unit capacity	KW		65
Hotboxes needed	units	15,385	15,385
MTAR's supply share	%	70%	80%
MTAR's Hotboxes share	units	10,769	12,308
Revenue/hotbox	USD	10,800	10,800
Total Revenue for MTAR	USDm	116	133
Total Revenue for MTAR	INRb	9.8	11.2

Source: MOFSL

Clean Energy – Fuel cells expected to retrace its growth trajectory



Source: MOFSL

Banks	MFI growth (% YoY, 2QFY25)	MFI Mix (%)
Federal Bank	75.8	1.8
AUSFB	NA	7.6
Bandhan Bank	9.8	45.4
RBL Bank	2.7	7.9
Equitas	-4.1	15.6
IDFC First Bank	-4.6	5.8
IndusInd Bank	-4.8	9.2

ICRA Webinar on NBFC-MFIs sector outlook

FY25 AUM growth to decline to 0-5%; Credit cost to peak at 5.4%-5.6%

The MFI and unsecured lending space are currently navigating a difficult landscape, characterized by a significant rise in bad loans. This trend has raised alarms about overleveraging and prompted warnings from regulators. RBI has implemented measures such as raising risk weights, while the MFIN has introduced tighter controls to rein in loan growth. ICRA hosted a webinar to discuss MFI industry trends, asset quality, and profitability outlook. The webinar was presented by Mr. Karthik Srinivasan, Senior Vice President & Group Head, Mr. A M Karthik, Senior Vice President & Co-Group Head, and Mr. Prateek Mittal, Assistance Vice President & Sector head. Following are the key insights from the session –

Asset quality deterioration led by overleveraging, socio-political disruptions, and operational challenges

- MFI asset quality deterioration is led by several factors –
 - a. **Borrowers Overleveraging:** The growing trend of borrowers having multiple lending relationships has led to a sharp rise in overall indebtedness. With debt spread across various lenders, borrowers faced increased financial pressure, making it difficult to manage repayments and thus contributing to financial instability.
 - b. **Climatic Impact:** Severe heatwaves, floods, and cyclones have significantly undermined asset quality.
 - c. **Socio-Political Disruptions:** Farmers' protests and loan waiver movements have led to write-offs, impacting asset quality.
 - d. **Operational Strain:** Challenges such as low center attendance, high field-level attrition, and rising door-to-door collections are affecting operations.
 - e. **High inflation has further aggravated the stress:** Post-COVID, many businesses and jobs were severely impacted, leading to increased borrowing and strong credit growth during a period of high liquidity. However, wage and business growth have not kept pace with inflation, which has been especially challenging for the rural households. As a result, there has been a de-prioritization of unsecured lending leading to rising delinquencies.

Near term stress to continue; condition expected to stabilize post 1QFY26

- Delinquencies (90+ DPD) in the NBFC-MFI sector have increased from 1.7% in FY20 to 2.2% in FY24, and are expected to rise further.
- The borrower rejection rate is expected to rise in the near term due to increasing financial strain on borrowers. Additionally, 20% of borrowers have more than three lenders, while 80% have one or two lenders. A significant unwinding of leverage, totaling INR400b, has already occurred.
- Asset quality is likely to further deteriorate in 2HFY25 due to customer over-leveraging and other macroeconomic factors. This period is transitional and unavoidable, with near-term stress expected in the current financial year and upto 1QFY26. However, conditions are expected to stabilize thereafter.

ICRA expects muted AUM growth at 0-5% in FY25 for NBFC-MFIs

- AUM growth in the NBFC-MFI sector has slowed significantly, dropping from 50% in FY18 to 29% in FY24, and is expected to decline sharply to 0-5% by end of FY25 given the rising concerns about asset quality.
- However, a recovery in AUM growth is anticipated from 2QFY26, with an estimated growth of 10-15% in FY26 driven by disbursement of high quality loans in MFI segment.

Credit cost to peak at 5.4%-5.6% in FY25; est. FY26 credit cost at 3.7-3.9%

- Credit costs have increased in 1HFY25 owing to stress in MFI industry. ICRA estimates credit cost to peak at ~5.4-5.6% by FY25 led by borrower overleveraging and operational challenges.
- Credit costs are expected to gradually decline in FY26 as lenders tighten their underwriting criterias alongside improved credit bureau checks. These checks now include validation of voter IDs with the help of multiple vendors, and efforts are also made to enhance the quality of other parameters, such as entering the last four digits of Aadhar, which will help streamline borrower identification.
- Additionally, addressing the overlap of loans across various sectors apart from MFI, such as gold loans, home loans, and agricultural KCC loans, will also ensure better underwriting and enable lower delinquencies, contributing to a reduction in credit costs. ICRA thus estimate credit cost to decline to 3.7-3.9% by the end of FY26.

Profitability trends to remain muted in near term; expect recovery in FY26

NIMs have remained under pressure in 1HFY25, largely due to decline in AUM growth in MFI sector and ongoing rise in funding costs. This compression in margins and rising credit costs may affect profitability in near future. ICRA expects RoA in the range of 0.4-0.8% in FY25 and this is likely to improve to 1.3-1.7% in FY26, with bulk of recovery anticipated during 2HFY26. Also, an additional funding of INR180-200b is required to support growth, apart from refinancing of existing/maturing lines.

Developments in the Banking Sector: Unsecured loan growth to moderate


- After a peak of 90.2% YoY growth in FY21, MFI lending growth has slowed to 13.1% in 2QFY25, with further moderation expected in the seasonally strong 2HFY25.
- Although the overall loan book continues to grow, the quality of new disbursements isn't very encouraging. Borrowers in some rural and semi-urban areas are experiencing income volatility, which is negatively affecting their repayment behavior.
- Growth for lenders has sharply declined from the high levels seen in FY24, with unsecured loan growth weakening further in 2QFY25, signaling a notable slowdown.
- The proportion of unsecured loans in the total loan book has decreased after years of growth. For banks, stress in the MFI segment and ongoing challenges in the credit card sector have contributed to slower growth. After peaking at 9.2% of total loans, the share has slightly moderated in 1HFY25, and is expected to decline further as unsecured loan growth continues to moderate.

■ MFI slippages have contributed disproportionately more to overall slippages of the lenders highlighting the significant stress within the sector. For Bandhan, MFI slippages accounted for 68% of total slippages, despite the MFI loan mix being only 47%. The situation is even more severe for RBL and IIB, where the ratio of MFI slippages to total slippages is 2-3 times higher than their MFI loan mix. We remain cautious and expect slippages to increase further in 3QFY25.

Outlook for FY26: RoA to recover to 1.3-1.7%

ICRA expects credit costs to decline to 3.7-3.9% by the end of FY26 after peaking in FY25. The industry, which had been growing at 30%, is now expected to grow at a slower rate of 10-15%. Southern states with higher per capita income (e.g., Kerala, Tamil Nadu) are performing better, even amidst adverse conditions like floods while states like Odisha and Jharkhand face significant challenges. The economy's cash flow in Nov and Dec has shown improvement, with positive signs emerging from the Kharif season and a good harvest, leading to optimism about increased cash availability. This, combined with the positive impacts of festival activities, is expected to boost disbursements and collection performance. RoA is expected to be in the range of 0.4-0.8% in FY25 and in the range of 1.3-1.7% in FY26.

Exhibit 1: Trend in Delinquencies of NBFC-MFIs (ICRA's sample set of companies)




Source: ICRA, MOFSL

Exhibit 2: Growth-trend of AUM of NBFC-MFIs to moderate in FY25



Source: ICRA, MOFSL


Exhibit 3: Projected trends in profitability metrics



Source: Data from various MFIs, ICRA Research; NIM – Net interest margin; Opex – Operating expenses; E – Estimated; P – Projected; All ratios are annualised and on average managed assets (AMA) basis; *The sample set consists of 22 MFIs, contributing around 95% to the AUM of NBFC-MFIs as on September 30, 2024


Source: ICRA, MOFSL

Exhibit 4: Declining growth in Unsecured Loans




Source: MOFSL

Exhibit 5: Unsecured loan book growth by banks for FY24 and 2QFY25




Source: MOFSL

Exhibit 6: MFI Slippages as a % of overall slippage of banks



Source: MOFSL

Exhibit 7: Unsecured and MFI Loan Mix as a Percentage of Total Loans by Bank




Source: MOFSL



Technology

PSYS tops the revenue contribution from healthcare vertical



Healthcare vertical: A pause in the party?

The healthcare vertical has been the fastest-growing vertical and has done heavy lifting for growth in recent times. However, with the potential return of Mr. Donald Trump as US President and the prospect of new healthcare reforms, there could be some short-term uncertainty in healthcare spending. In this note, we explore how these potential changes might impact the healthcare sector and what it could mean for the vertical's growth trajectory. We also examine the implications for Indian IT companies with significant exposure to this sector, assessing how their performance might be influenced by the shifts in the US healthcare landscape.

US healthcare: Bracing for impact

- Mr. Trump's second term is likely to bring many changes to US healthcare policy, with a focus on repealing the Affordable Care Act (ACA), altering Medicaid funding mechanisms, and potentially reshaping drug pricing regulations.
- The healthcare industry is bracing for these shifts, indicating expectations of a more favorable environment for private insurers and Medicare Advantage plans.
- Mr. Trump's reelection is likely to have a mixed impact on providers and hospitals, which face challenges from reduced reimbursements and rising costs.
- The life sciences sector has a mixed outlook, with expedited FDA approvals boosting revenues but increased scrutiny on drug pricing pressuring margins.

Indian IT: Healthcare structurally strong, could have short-term snags

- Persistent Systems (PSYS) has the highest reliance on the healthcare vertical with 28% revenue contribution, followed by HCL Tech (16%) and Wipro (14%).
- PSYS has achieved impressive growth, averaging 51% YoY, in its healthcare vertical over the last four quarters on the back of the ramp-up of large deals. While this has to moderate going forward as the initial ramp-up recedes, we believe the company could continue to deliver growth as BFS and Hi-tech, its two other key verticals, recover in FY26.
- HCLT's healthcare vertical has been slightly erratic (down 4% QoQ in 1QFY25 followed by ~3% growth in 2QFY25), whereas for Wipro it has clocked an ~8.5% CAGR over the past two years, underscoring structural tailwinds in the sector.

Plotting the recovery: Healthcare ranks one

- As highlighted in our recent thematic report ([Bounce-Back! Charting the path to revival for the IT services](#)), we expect healthcare to be the fastest-growing vertical over the medium to long term due to neutral tailwinds from rate cuts, a low threat of insourcing, and stable spends backed by the need for investment in drug discovery, biotechnology and clinical trials.
- However, we would watch out for commentary on the vertical in the upcoming earnings season and a potential impact from the new administration in the US. While we expect growth to moderate in the short term, it should resume once policy clarity emerges in 1HCY25.



Maruti Suzuki: Have Reached A Historic Milestone Of 2 M Units Produced In A Calendar Year; Rahul Bharti, Executive Director

- 2.9 lakh units were exported, showcasing global reach.
- India to reach 6.5 million cars/year by 2030.
- Exports expected to triple by the end of the decade.
- Maruti's production surpasses entire countries like France and Canada.
- Retail sales growth anticipated to be between 3-4%.

[➔ Read More](#)

Route Mobile: Now We Have A Global Footprint, Will Be A Differentiator For Large Scale Opportunities; Rajdipkumar Gupta, MD

- Projected collective revenue of approximately \$2 billion.
- Enhanced ability to pursue large-scale strategic opportunities.
- Expected global EBITDA synergies of €100 million.
- Focus on driving operational efficiency post-integration.
- Maintaining revenue guidance of 18-22% growth and 13-13% margins.

[➔ Read More](#)

One MobiKwik: Distribution Of Insurance, Credit Products, Savings Products Will Be Key For Growth; Upasana Taku, Chairperson & CFO

- The company aims for 50-59% growth, focusing on sustainable expansion.
- Distribution of insurance, savings, and credit products to enhance revenue.
- MobiKwik has 161 million users, with a significant percentage having full KYC.
- Achieved profitability in FY24, indicating a positive financial trend.
- Fixed costs are decreasing, allowing for better margins as revenue grows.
- Digital payments remain the foundation, driving user acquisition and merchant growth.

[➔ Read More](#)

Narayana Health: Not Doing Premium Pricing As Yet As Robotic Surgeries Not Yet Margin Accretive; Sandhya J, Group CFO

- Opportunistic about M&A but cautious due to high asset prices in India.
- Affordability issues remain, particularly for the "missing middle" demographic.
- Only about half of the surgeries needed in India are being performed.
- The company is expanding its robotic surgery program, aiming for 10,000 surgeries annually.
- Price increases for procedures will be in the low single digits, primarily to cover inflation.
- Robotic surgeries improve recovery times but currently do not offer significant cost reductions.

[➔ Read More](#)

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- managed or co-managed public offering of securities from subject company of this research report,
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

- a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
- (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement	Companies where there is interest
Analyst ownership of the stock	No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under

applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemanj Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.